Date Title Description PDF
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
20 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 13 December 2021 and 17 December 2021 Download
17 Dec 2021 On business and financial situation ROVI reports that the CHMP has issued a positive opinion on Okedi® for the treatment for schizophrenia Download
13 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 6 December 2021 and 10 December 2021 Download
06 Dec 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 29 November 2021 and 3 December 2021 Download
22 Nov 2021 Share buy-back , stabilisation and treasury stock programmes Share Buyback Program: transactions conducted between 15 November 2021 and 19 November 2021 Download

Pages

Date Title Description PDF
21 Feb 2013 Información sobre resultados (2) Download
21 Feb 2013 Información sobre resultados Download
21 Feb 2013 Informe Anual de Gobierno Corporativo 2012 Download
08 Nov 2012 Información financiera intermedia Download
08 Nov 2012 Información sobre resultados Download

Pages